Clinical trials: Glial Tumor
Malignant Glioma
Dendritic Cell (DC) Activated Cytokine-induced Killer Cell (DCIK) Combined With DC Treatment for Glioma
Malignant gliomas are very aggressive and among the most common of brain tumors. A diagnosis carries with it a median survival of approximately 12 months, with 90 - 95% of patients surviving less than 2 years.
- Trial name
- NCT01235845
- Testing
- Biological: DC activated CIK combined with DC
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Qingdao University
Brain and Central Nervous System Tumors, Melanoma (Skin)
Boron Neutron Capture Therapy in Treating Patients With Glioblastoma Multiforme or Melanoma Metastatic to the Brain
RATIONALE: Radiation therapy such as boron neutron capture therapy may kill tumor cells without harming normal tissue. PURPOSE: Phase I/II trial to study the effectiveness of boron neutron capture therapy in treating patients who…
- Conditions
- Brain and Central Nervous System Tumors, Melanoma (Skin), Metastatic Cancer
- Trial name
- NCT00039572
- Testing
- boronophenylalanine-fructose complex
- Where
- 2 sites in United States
- Sponsor
- Beth Israel Deaconess Medical Center
Mesothelioma, Glioblastoma
Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
Study of NGM707 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
- Conditions
- Mesothelioma, Glioblastoma, Renal Cell Carcinoma, Non Small Cell Lung Cancer
- Trial name
- NCT04913337
- Testing
- NGM707, NGM707 plus pembrolizumab (KEYTRUDA®)
- Where
- 27 sites in United States, South Korea and 1 more
- Volunteers
- 179 people
- Sponsor
- NGM Biopharmaceuticals, Inc
Anaplastic Astrocytoma, Glioblastoma
Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations
This phase II trial studies how well veliparib, radiation therapy, and temozolomide work in treating patients with newly diagnosed malignant glioma without H3 K27M or BRAFV600 mutations.
- Conditions
- Anaplastic Astrocytoma, Glioblastoma, Malignant Glioma
- Trial name
- NCT03581292
- Testing
- Radiation Therapy, Temozolomide, Veliparib
- Where
- 163 sites in United States, Australia and 3 more
- Volunteers
- 38 people
- Sponsor
- Children's Oncology Group
Glioblastoma
Nimotuzumab Plus Radiotherapy With Concomitant and Adjuvant Temozolomide for Cerebral Glioblastoma
This study aimed to investigate the clinical benefit contribution and safety of nimotuzumab to the standard combined treatment for patients with newly diagnosed glioblastoma.
- Trial name
- NCT03388372
- Testing
- Nimotuzumab, Temozolomide, Radiotherapy
- Where
- 5 sites in China
- Volunteers
- 39 people
- Sponsor
- Biotech Pharmaceutical Co., Ltd.
Pediatric Recurrent Progressive Low-grade Gliomas, Pediatric Progressive Low-grade Gliomas
PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children
This is an open label study of everolimus in children with recurrent or progressive low-grade glioma.
- Trial name
- NCT01734512
- Testing
- Everolimus
- Where
- 18 sites in United States
- Volunteers
- 65 people
- Sponsor
- University of California, San Francisco
Malignant Glioma, Glioma
A Study of Aminolevulinic Acid Used to Enhance Visualization and Surgical Removal of Brain Tumors
In this study subjects will be administered a single oral dose of Aminolevulinic Acid (ALA) prior to surgical resection of their brain tumor.
- Conditions
- Malignant Glioma, Glioma, Glioblastoma, Glioblastoma Multiforme
- Trial name
- NCT01351519
- Testing
- Aminolevulinic Acid
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- MultiCare Health System Research Institute
Glioma
fMRI Reveal Functional Preservation in Glioma Peritumoral Edema
he goal of this observational study is to investigate the functional and biological characteristics of the brain tissue surrounding diffuse gliomas, known as peritumoral edema (PTE).
- Trial name
- NCT07343492
- Where
- China
- Volunteers
- 44 people
- Sponsor
- West China Hospital
Neoplastic Disease, Glioblastoma
131I-TLX-101 for Treatment of Newly Diagnosed Glioblastoma (IPAX-2)
This is an open label, single arm, parallel-group, multicentre, and dose finding study to evaluate the safety of ascending radioactive dose levels of 131I-TLX101 administered intravenously in combination with best standard of…
- Conditions
- Neoplastic Disease, Glioblastoma, Glioblastoma Multiforme
- Trial name
- IPAX-2 (NCT05450744)
- Testing
- 131I-IPA
- Where
- 5 sites in Australia, Austria and 1 more
- Volunteers
- 12 people
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
Glioblastoma Multiforme, Anaplastic Astrocytoma
Loupe-Based Intraoperative Fluorescence Imaging
Glioblastoma multiforme (GBM) and anaplastic astrocytoma (AA) are the most common primary malignant brain tumors. Survival of patients with these brain tumors is directly related to the extent of resection.
- Trial name
- NCT04780009
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Guoqiang Yu
Brain and Central Nervous System Tumors, Hereditary Wilms Tumor
Gene Mutation in Samples From Young Patients With Pleuropulmonary Blastoma Syndrome at Risk for Developing Cancer
RATIONALE: The identification of gene mutations in young patients with pleuropulmonary blastoma syndrome may allow doctors to better understand the genetic processes involved in the development of some types of cancer, and may…
- Conditions
- Brain and Central Nervous System Tumors, Hereditary Wilms Tumor, Kidney Cancer, Liver Cancer
- Trial name
- NCT01353300
- Testing
- DNA analysis, cytogenetic analysis, gene expression analysis
- Volunteers
- 31 people
- Sponsor
- Children's Oncology Group
Constitutional Mismatch Repair Deficiency Syndrome, Lynch Syndrome
Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma
This phase I trial studies the side effects and best dose of pembrolizumab and to see how well it works in treating younger patients with high-grade gliomas (brain tumors that are generally expected to be fast growing and…
- Conditions
- Constitutional Mismatch Repair Deficiency Syndrome, Lynch Syndrome, Malignant Glioma, Recurrent Brain Neoplasm
- Trial name
- NCT02359565
- Testing
- Biospecimen Collection, Conventional Magnetic Resonance Imaging, Diffusion Tensor Imaging
- Where
- 12 sites in United States, Canada
- Volunteers
- 71 people
- Sponsor
- National Cancer Institute (NCI)
Glioblastoma, Recurrent Glioblastoma
Identification of Treatment Concentrations of Defactinib or VS-6766 for the Treatment of Patients With Glioblastoma
This early phase I trial tests brain concentration level and safety of defactinib or VS-6766 for the treatment of patients with glioblastoma.
- Trial name
- NCT05798507
- Testing
- Avutometinib, Biospecimen Collection, Defactinib
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Emory University
Glioblastoma, Adult, EGFR Amplification
GC1118 in Recurrent Glioblastoma Patients With High EGFR Amplification
This study is a phase 2 trial of GC1118, an EGFR monoclonal antibody, for recurrent glioblastoma patients who were treated with standard concurrent chemoradiation.
- Trial name
- NCT03618667
- Testing
- GC1118
- Where
- South Korea
- Volunteers
- 13 people
- Sponsor
- Samsung Medical Center
Advanced Solid Tumors
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
This is a first-in-human, Phase 1/2 study to evaluate LCB84, a TROP2-directed antibody-drug conjugate, alone and in combination with an anti-PD-1 Ab, in dose escalation (Phase 1) followed by dose expansion (Phase 2).
- Trial name
- NCT05941507
- Testing
- LCB84, Anti-PD-1 monoclonal antibody
- Where
- 8 sites in United States, Canada
- Volunteers
- 300 people
- Sponsor
- LigaChem Biosciences, Inc.
Glioma, Glioma (Diagnosis)
GliomaAI-Astro4: MRI-Based Detection of IDH Mutant Astrocytoma Grade 4
The goal of this observational study is to learn whether an artificial intelligence system called GliomaAI-Astro4 can help detect a specific molecular type of brain tumour called IDH mutant Astrocytoma Grade 4 using routine MRI…
- Conditions
- Glioma, Glioma (Diagnosis), Astrocytoma, Astrocytoma, Grade IV
- Trial name
- GliomaAI-A4 (NCT07673679)
- Testing
- GliomaAI-Astro4
- Where
- India
- Volunteers
- 1,372 people
- Sponsor
- Deep Learning Institute of Radiological Sciences
Brain Tumor, Glioma
Metabolic Characterization of Space Occupying Lesions of the Brain
High field MR-technologies are expected to boost metabolic spectroscopic imaging (MRSI), but also CEST-MRI. This is due to the fact that increased SNR is available which can be used to increase the spatial resolution of all…
- Conditions
- Brain Tumor, Glioma, IDH Mutation
- Trial name
- FASTMRSI (NCT04233788)
- Testing
- MR-scans using a 3T Prisma and a 7T Terra scanner (Siemens, Erlangen Germany)
- Where
- Switzerland
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Low Grade Glioma, World Health Organization (WHO) Grade II Astrocytomas
Everolimus With and Without Temozolomide in Adult Low Grade Glioma
The purpose of this study is to find out what effects, good and/or bad, everolimus (RAD001, also known as Afinitor®) alone or with temozolomide has on the patient and the patient's low-grade glioma.
- Conditions
- Low Grade Glioma, World Health Organization (WHO) Grade II Astrocytomas, Oligodendrogliomas, Mixed Oligoastrocytomas
- Trial name
- NCT02023905
- Testing
- Everolimus, Temozolomide
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of California, San Francisco
Glioblastoma, Glioma
Radiomics for Prediction of Survival in GBM
Radiomics, the extraction of large amounts of quantitative image features to convert medical images into minable data, is an in-development field that intends to provide accurate risk stratification of oncologic patients.
- Conditions
- Glioblastoma, Glioma, Astrocytoma
- Trial name
- Radiomics (NCT02666066)
- Where
- Netherlands
- Volunteers
- 289 people
- Sponsor
- Maastricht Radiation Oncology
Glioblastoma, High-grade Glioma
Multispectral Bimodal Fluorescence Guided Surgery of High-grade Glioma With Cetuximab-800CW and 5-ALA (5-aminolevulinic Acid)
The MIRROR study is a prospective, single center phase I feasibility and dose finding study in patients with high-grade glioma, to establish the safety, feasibility, and optimal dosage of Cetuximab-IRDye800CW for fluorescence…
- Trial name
- MIRROR (NCT05929456)
- Testing
- Cetuximab-IRDye800
- Where
- Netherlands
- Volunteers
- 21 people
- Sponsor
- University Medical Center Groningen
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.